$15.47-0.8%Nov 13 close
Figures through August 31, 2026, from the 10-Q filed October 13, 2026
Nurix licenses rights to experimental cancer drugs and protein-degradation research to pharmaceutical companies, while developing its own cancer and immune-disease medicines.
The quarter ending August 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toAug 31, 2026 | 3 months toAug 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $673.1M | $7.9M | +8,426.27% |
| Profit | $549.8M | -$86.4M | +736.20% |
| Profit per share | $4.73 | -$1.03 | +559.22% |
| Free Cash Flow | $614.2M | -$60.1M | +1,122.10% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
(NX-5948) Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche across malignant hematology, immunology and neurology. Bexobrutideg is currently being evaluated in a broad clinical development program in patients with CLL, including DAYBreak CLL-201 (NCT07221500), a pivotal single-arm Phase 2 study in relapsed/refractory CLL; DAYBreak CLL-306 (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL; NX-5948-203 (NCT07520006), a Phase 1b/2 study evaluating bexobrutideg in combination with venetoclax with or without an anti-CD20 antibody in relapsed/refractory and treatment-naïve CLL; and NX-5948-301 (NCT05131022), a Phase 1a/1b study in relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nurix Therapeutics, Inc.’s Item 2.02 8-K filed October 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Nurix Therapeutics, Inc. has no earnings call transcript available.
Results released October 13, 2026, before the market closed
Shares were essentially flat as Roche financing and Phase 3 progress were offset by one-off-heavy earnings and the discontinued NX-2127 program.
Into the report: -11.7% over a month, -3.6% over three months, -20.3% from the year's high.
Written by AI on October 23, 2026 from Nurix Therapeutics, Inc.'s results releases, earnings call and SEC filings; every quote it relied on was checked against them. It describes the report, it is not investment advice, and it is in English only.